Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $102.19M.
ENTERPRISE VALUE (EV)
$102.19M
Caribou Biosciences, Inc.
Market Cap
$114.55M
Enterprise Value (EV)
$102.19M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | $114.55M | $102.19M |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.52M | $106.03M |
| Genelux Corporation (GNLX)vs › | $114.76M | $108.00M |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | $116.29M |
| Coya Therapeutics, Inc. (COYA)vs › | $115.61M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $113.21M | $88.23M |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $113.07M | $69.56M |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $112.69M | $97.56M |
| BGM Group Ltd. (BGM)vs › | $117.61M | $107.27M |
| Spruce Biosciences, Inc. (SPRB)vs › | $119.21M | $30.59M |
Market Cap
$114.55M
Total Debt
$0.00
Cash
$12.36M
Enterprise Value
$102.19M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
